Revenue Differences Between Top-Selling Small-Molecule Drugs and Biologics in Medicare
This study compares the revenues earned by manufacturers 9 vs 13 years following US Food and Drug Administration approval for negotiation-eligible products from 2012 to 2022.
Authors
- Matthew Vogel (ORCID: https://orcid.org/0009-0005-5216-444X)
- Anchal Chandra (ORCID: https://orcid.org/0000-0003-4096-4771)
- William B. Feldman (ORCID: https://orcid.org/0000-0003-3467-5869)
- Aaron Seth Kesselheim (ORCID: https://orcid.org/0000-0002-8867-2666)
- Benjamin N. Rome (ORCID: https://orcid.org/0000-0001-5776-3293)
- Olivier J. Wouters (ORCID: https://orcid.org/0000-0002-2514-476X)
- Zander Cowan
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- John F. Kennedy University (US)
- Brown University (US)
Publication Details
- Journal
- JAMA Health Forum
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1001/jamahealthforum.2025.4720
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- World Health Organization
- Arnold Ventures
- National Institutes of Health